It is well known that
Helicobacter pylori
(
H. pylori) infection is the major cause of gastric ulcers (GU) and eradication
of the infection can reduce the occurrence and recurrence of GU. Many different
therapeutic strategies performed might have caused some confusion for therapists,
hence causing some disadvantages for cost-effectiveness to public health care.
To standardize the therapy for GU patients in Japan, an evidence-based guideline
(GL) with the provision of an explanatory flow chart (
Fig. 1) was first
published in 2003 (1
st version) (1) and then in
2007 (2
nd version)(2) with a minor revision under
the support of the Japanese Ministry of Health, Labor and Welfare (GUGLJ).
|
Fig. 1. Flow chart of treatments
in the EBM-based Guideline for Gastric Ulcer in Japan. |
It is believed that clinical practice with GLs can improve the quality, appropriateness and cost-effectiveness of health care, and can also serve as valuable education tools. Among 279 GL published from 1985 to 1997, however, the mean adherence to standards by each GL was low, estimated at 43.1% according to the standards for GL development established by Shaneyfelt
et al. in 1999 (3). On the other hand, adherence of GUGLJ to these standards is high, estimated at 80% (1). Theoretically, the degree of doctor’s knowledge on the GUGLJ and their respective specialties may relate to the degree of their adherence to the GUGLJ for the treatment of the GU patients. A stronger adherence of doctors in charge indicate a stronger adherence to treatment performed for GU patients, which may have resulted in more effective treatment of the GU. Effectiveness means managed and improved control of GU with less expense of the therapy performed. Assessment and eradication of
H. pylori is important to control gastric cancer development as well, which can follow the
H. pylori induced chronic gastritis (4). The present study herein has been designed to perform a multihospital analysis to assess the relationship of a doctor’s knowledge and specialty for the GUGLJ and the medical cost utilized for the complete treatment of a GU patient, and is referred to as “Japan assessment study on the evidence-based guideline for gastric ulcer with special reference to its outcome: EGGU.” To date, no other papers surveying the nationwide cost-effectiveness of GUGLJ-based therapy of GU patients have been published in Japan.
MATERIALS AND METHODS
Gastric ulcer patients and doctors in charge
The present study was a retrospective cohort analysis. GU patients with active
ulcers diagnosed by an endoscopic examination between September 2004 and April
2005, and doctors in charge that treated the patients at NHO hospitals were
enrolled through an internet registration on the EGGU web site between May 2006
and March 2007. Patients were selected to be
20
years old on April 1, 2006, or
18
years old at the time of GU diagnosed.
Patients were examined for their subjective symptoms relating to the ulcer healing or recurrence when they were enrolled in the present study after the treatment of GU by inquiring about their health conditions
via mail between May 2006 and March 2007. Health status assessment was performed using SF36, version 2 (5). Those doctors in charge enrolled in the study were surveyed by the EGGU researcher at each hospital by their specialty, whether gastrointestinal (GI) experts, non-GI physicians or other specialists. Their knowledge regarding the GUGLJ was divided into 3 groups based on by the answer to the inquiries about the GUGLJ: knew it very well, just yes or no. Medical records of each patient were examined to discover the endoscopic findings of the ulcer healing or recurrence, and the medical treatments performed. Adherence scores to the GUGLJ were adapted to each category of performance for the therapy of GU. The total adherence scores were calculated by counting the number of performances and their adherence scores. The present study was undertaken with permission from the ethical committee of the NHO in Japan. All doctors and patients involved with the study had signed their informed consents.
Flow chart described in the guideline
Active ulcers are initially checked to determine if they bleed or not. After
the bleeding stops or no bleeding is recognized, assessment for non-steroidal
anti-inflammatory drugs (NSAID) intake and
H. pylori infection is undertaken.
If
H. pylori infection is positively identified, and its eradication
is performed successfully, no maintenance therapy is requested following the
eradication. This flow chart can clearly inform the doctors in charge of the
treatment strategy of the GU patient (
Fig. 1).
Guideline adherence scores
In order to calculate the GUGLJ adherence scores, five items shown in
Table
1 were scored. They were 1) NSAID; 2)
H. pylori infection; 3) ulcer
healing treatment; 4) maintenance therapy; and 5) therapy for patients with
no
H. pylori infection. “Comments” in
Table 1 indicated the different
activities of the doctors in charge or therapies performed; and “Therapies”
indicated the drugs prescribed to the GU patients. For example, the presence
of description about NSAID intake or the assessment for
H. pylori infection
by the doctor in charge in the medical records was scored 5. On the other hand,
no description in the medical records about these two items was scored 0. These
scores were determined by the significance for the therapy, which is reflected
in the flow chart of the GUGLJ. Finally, the total GUGLJ adherence scores counted
were divided into 4 groups: category 1 with a total score of
5,
category 2 with a total score of
6
and
12, category
3 with a total score of
13
and
20, and category
4 with a total score of
21;
the larger category number indicates greater adherences to the GUGLJ. These
categories were drawn from the retrospective assessments of the medical record
of each GU patient, not from the subjective memory of the doctors in charge.
Compliance of the GU patients was not analyzed because it was subjective and
difficult to estimate. Subjective data were limited to the health status assessment
of GU patients using SF36 version 2. Since the adherence scores and categories
were counted utilizing only the objective findings described in the medical
record of GU patients, they should be highly reliable.
Table 1. Guideline
adherence scores. |
|
Abbreviations: NSAID,
non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitors; H2B,
H2 blocker (histamine H2
receptor antagonists); MP, mucosal protectants; MTx, maintenance therapy |
Health status assessment
For the health status assessment of GU patients, SF36 version 2 (5) was applied. This is a program accepted worldwide to assess the health-related quality of life (QOL) of patients. SF36 is a popular tool to compare the patient’s physical and mental condition among different diseases. It includes eight subscales: physical functioning (PF), role physical (RP), bodily pain (BP), social functioning (SF), general health perceptions (GH), vitality (VT), role emotional (RE) and mental health (NH), and two summary scores: physical component summary (PCS) and mental component summary (MCS). Letters of inquiry were delivered to each patient and the answers returned to the EGGU office by mail by patient’s own voluntary participation.
Medical cost utilized for the treatment of gastric ulcer
The relationship between the adherence scores to GUGLJ and the medical cost consumed during the following nine months after the diagnosis of GU was analyzed. All data described in the medical records of GU patients that consulted the NHO hospitals enrolled were analyzed. If the GU patients consulted hospitals other than an NHO hospital, or they consulted the NHO hospitals as result of other conditions, those data were not included in the analysis. When the period of prescription for GU was recorded longer than nine months, the data were excluded from the analysis. Accounting of the medical cost expended was done based on the drugs prescribed, the endoscopic examinations performed, and the medical cost of outpatient clinic and inpatient hospitalization. These accounts were basically done with respect to the National Health Insurance points of Japan. The medical costs of drugs prescribed were accounted for by counting the volume of drugs per day and the duration of drugs prescribed. Generic or non-generic brands of the drugs prescribed were also included in the accounting process. The medical costs of the outpatient clinics were accounted for by counting the number of consultations, and the fees of consultation and prescription with respect to health care insurance. We found that the average duration of hospitalization for GU/duodenal ulcer (DU) was 22.5 days. The National Health Insurance points of GU/DU have been published in the data of the Diagnosis Procedure Combination (DPC) system of the Japanese Ministry of Health, Labor and Welfare. The medical cost consumed for GU/DU therapy in a one-day inpatient hospitalization was accounted for by dividing the National Health Insurance points of GU/DU by 22.5. Then, the total costs of inpatient hospitalization were assessed with that of one-day inpatient hospitalization and the duration of inpatient hospitalization recorded. Finally, the cost of one endoscopic examination, one-day consultation for GU, and one-day inpatient hospitalization for GU were estimated at 11,400; 1,380; and 26,410 Japanese Yen, respectively.
Statistical analysis
The base-line characteristics of the patients and doctors enrolled were compared
by the Student’s t-test. Recurrence rates of GU, the medical performances and
the GUGLJ adherence scores, the description of whether the patient was a NSAID
taker or not, and the assessment of
H. pylori infection were compared
by the chi-square test or Student’s t-test. Because the QOL-scores and the medical
costs consumed are influenced by gender, age and complications of the GU patients,
and whether the patients were NSAID taker or not, the associations between the
GUGLJ adherence score and PCS/MCS or the medical cost consumed were investigated
by adjusting these factors by a multiple regression analysis using software
of JMP8 (SAS Institute Inc., Cary, NC, USA) or STATA11 (StataCorp., Texas, USA),
respectively. Different medical costs expended of category 1 to 4 were investigated
by the Kruskal-Wallis test. Significance was indicated by a
P value of
less than 0.05.
RESULTS
Patients
Initially, 942 GU patients were enrolled but seven patients were dropped out during the follow-up period. Therefore, a total of 935 patients (572 male, 363 female, average age =63.9 years) were enrolled. Out of these GU patients, 283 (30.3%) had a past history of GU and 554 (59.3%) had complications; diabetes in 100, hypertension in 176, heart disease in 107, vascular disease in 107, liver disease in 79 and others in 302. For the GU patients, description whether the patient was an NSAID-taker or not was found in 847 (90.6%) of their medical records, and 162 (17.3%) were NSAID-takers.
H. pylori infection assessment was performed in 622 (66.5%). Of these GU patients, 75.6% were
H. pylori positive and 24.4% were negative. Assessment of eradication was performed in 81.3% of
H. pylori-positive GU patients, and 86.8% of them succeeded in total eradication.
Doctors in charge of the gastric ulcer patients
In total, 270 doctors (232 male, 38 female, average age =40.9) from 62 NHO hospitals were enrolled. There were 173 (64.1%) GI experts, and 70 (25.9%) non-GI physicians. The doctors in other fields numbered 27 (10.0%). Regarding inquiries about the GUGLJ, 79 (29.3%) doctors in charge answered “yes very well.”, 128 (47.4%) answered just “yes.” and 63 (23.3%) answered “no.”
Recurrence of gastric ulcer with respect to NSAID status and eradication of Helicobacter pylori
NSAID-takers tended to show higher GU recurrence rates than NSAID non-takers,
but there was no statistical significance between them (
Table 2). On
the contrary, the eradication may contribute to the reduction of the GU recurrence
in the
H. pylori-positive GU patients. Among
H. pylori-positive
patients, the GU recurrence rates were significantly lower in patients with
successful eradication than those with failure eradication either NSAID takers
or not (
Table 3).
Table 2. Relationships
among NSAIDs intake and recurrence in the Helicobacter pylori negative
gastric ulcer patients. |
|
Abbreviations: NSAID,
non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitors |
Table 3. Relationships
among NSAID intake, eradication and recurrence in Helicobactor pylori
positive gastric ulcer patients. |
|
aP=0.003;
bP=0.03; cP=0.04
Abbreviations: NSAID, non-steroidal anti-inflammatory drugs; PPI, proton
pump inhibitors |
Specialty and performance of doctors in charge of the gasatric ulcer patients
Table 4 shows that a description of a GU patient being an NSAID-taker
or not was related significantly (
P<0.001) to the specialty of the doctors
in charge. On the other hand, the assessment of
H. pylori infection was
carried out most frequently (P=0.002) by the doctors in charge who knew the
GUGLJ very well. There were no statistically significant relationships between
these performances and the GU recurrence (data not shown).
Table 4. Relationships
between specialities of doctors and their performance among 927 patients
treated. |
|
Abbreviations: NSAID,
non-steroidal anti-inflammatory drugs; H, Helicobacter; GI, gastrointestinal
experts; non-GI, non-GI physicians; Does the doctor know about the guideline
(GL)? Yv, Yes. I know it very well.; Y, Yes. I know it.; N, No. I do not
know it. |
Therapeutic drugs prescribed
Proton pump inhibitors (PPI) were most frequently prescribed in 30.4% of the
935 GU patients. Among 162 NSAID-takers, 51.2% quitted NSAID intake after the
diagnosis of GU. No maintenance therapy was undertaken in 24.4% of 250
H.
pylori-positive GU patients with successful eradication. Among them, histamine
H
2 receptor antagonists (H
2RA)
were prescribed most frequently. On the other hand, among
H. pylori-positive
GU patients with failure eradication and
H. pylori-positive GU patients
with no assessment of the eradication performed, no maintenance therapy was
undertaken less frequently, and a PPI was prescribed in double frequency as
compared with those for the former 250 GU patients. Among
H. pylori-negative
patients, a PPI was prescribed most frequently (
Table 5).
Table 5. Therapies
for gastric ulcer patients |
|
Abbreviations: NSAID,
non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitors; H2RA,
histamine H2 receptor antagonists; MP,
mucosal protectants; MTx, maintenance therapy |
Guideline adherence scores
In total, 927 GU patients were analyzed for the GUGLJ adherence scores. The
scores showed a significant relationship to the specialty (
P<0.05), and
the knowledge (
P<0.001) of the doctors in charge (
Table 6). There
were no statistically significant relationships identified between these categories
and the GU recurrence (data not shown).
Table 6. Relationships
between guideline adherence scores and number of patients treated |
|
Abbreviations: GI, gastrointestinal
experts; non-GI, non-GI physicians; Av, average of Category 1, Scores
5; 2, Scores
6 and 12;
3, Scores 13
and 20; 4,
Scores 21;
Does doctor know about the guideline (GL)? Yv, Yes. I know it very well.;
Y, Yes. I know it.; N, No. I do not know it. |
Quality of life of the gastric ulcer patients
To assess the health-related quality of life (QOL) of the GU patients, the SF-36
version 2 was applied. Results indicated that the highest point was scored in
the category 4 in all of the subscales (
Fig. 2). These subscale scores
tended to be higher in male patients, less than 65 of age, no GU recurrence
and NSAID non-takers. Then, the relationship between the subscale scores and
the GUGLJ adherence scores were examined by a multiple regression analysis with
respect to the gender, age and complications of the GU patients, and whether
they were NSAID-takers or not. The subscales showed a significant relationship
(
P<0.01) to the PCS, but not to the MCS of SF-36 (data not shown).
|
Fig. 2. Guideline adherence
scores and the subscales of SF-36. Category 1, Scores 5;
2, Scores 6
and 12; 3,
Scores 13 and
20; 4, Scores
21; PF, physical
functioning; RP, role physical; BP, bodily pain; SF, social functioning;
GH, general health perceptions; VT, vitality; RE, role emotional; NH,
mental health. |
Direct medical cost expended for the treatment of gastric ulcers
There was a significant difference (
P<0.001) in the medical cost consumed
among the four categories of the adherence to the GUGLJ scores (
Table 7).
The total medical cost for these performances in category 4 was calculated as
237,467 Japanese yen, which was 67% of that in category 1, and the least expensive
among the four categories with statistical significance (
P<0.001) (
Fig.
3). The complications of the GU patients, whether they were NSAID takers
or not, and the GUGLJ adherence score were associated with total medical cost
(
Table 8).
Table 7. Relationships
between guideline adherence scores and medical costs consumed for treatment
of gastric ulcer. |
|
aP<0.001,
bP=0.037, cP<0.001,
dP=0.013;
Abbreviations: Category 1, Scores 5;
2, Scores 6
and 12; 3,
Scores 13 and
20; 4, Scores
21; |
|
Fig. 3. Guideline adherence
scores and the direct medical cost consumed for the GU therapy. Category
1, Scores 5;
2, Scores 6
and 12; 3,
Scores 13 and
20; 4, Scores
21. |
Table 8. Multiple
regression analysis for total medical cost expended. |
|
Total medical cost was
log transformed.
Adjusted R squared=0.0834
Age and gender were excluded for the final model because of no statistical
significance in the multivariate model.
Abbreviations: Category 1, Scores 5;
2, Scores 6
and 12; 3,
Scores 13 and
20; 4, Scores
21; |
DISCUSSION
H. pylori is an important factor in the pathogenesis of gastro-intestinal
disorders.(6, 7). In the past,
H. pylori infection has been detected
in a range of 56 to 96% of GU patients. This difference may be reflecting the
different use of the NSAID among the GU patients (8). In the present study,
H. pylori infection was detected in 75.6% and NSAID intake was found
in 17.3% of GU patients.
H. pylori and NSAID are known to correlate with
the GU recurrence.
H. pylori infection can increase the risk of GU by
an odds ratio of 3.2 (9), and the risk of GU in
H. pylori-infected NSAID
takers was estimated at 61.1 times higher compared with
H. pylori-negative
NSAID non-takers (10). Concerning the use of NSAIDs is the basic issue for GU
treatment. The GUGLJ recommends the doctors in charge to perform GU therapy
after quitting NSAID intake, if possible. In practice in the present study,
90.6% of GU patients were examined for NSAID intake. The doctors in the other
fields than the physicians recorded it less frequently. 51.2% of the NSAID-takers
quitted the use of NSAID and 79.0% of them received the PPI treatment. PPI treatment
is the first choice for the GU patients with no
H. pylori- infection
or failure eradication, and H
2RA is the second
choice in case of failure eradication according to the GUGLJ. In the present
study, PPI and H
2RA were prescribed most frequently
for the GU patients with no
H. pylori-infection and failure eradication,
respectively.
H. pylori assessment was performed in 66.5% of GU patients.
Doctors who knew the GUGLJ very well did this assessment most frequently. These
different specialties or knowledge of doctors in charge may relate to the different
GU treatment or the low performance rate of
H. pylori assessment. In
fact, the GI-experts and the doctors in charge that knew the GUGLJ very well
treated the most GU patients in category 4.
In case of no
H. pylori infection, GU recurred in 12.1% of patients, which was confirmed with an endoscopic examination. When the failure eradication occurred among the
H. pylori-positive GU patients, the endoscopic GU recurrence rates increased significantly up to 50% of NSAID-takers and 29.2% of NSAID non-takers. Therefore, the eradication is important to achieve the effective treatment of GU. The GUGLJ recommended several ways of eradiation and expected that the successful eradication to be performed. However, it does not exclude the failure eradication itself, since the latter still occurs in substantial numbers even if the ideal eradication has been undertaken. In the present study, no scores were adapted to the failure eradication.
Prescribed aids of GU treatment are to relieve the pain, to promote ulcer healing,
and to prevent ulcer recurrence. The eradication therapy could heal GU effectively
except for the pain relief and reduce the GU recurrence rate after one year
compared to the therapy with acid blockers (11). It was reported that the maintenance
therapy with acid blockers and mucosal protectants was insufficient to prevent
GU recurrence since 24.6% of GU recurred one year after this combination therapy
through the primary care and maintenance therapy of GU in Japan. Labenz
et
al. reported no necessity of the maintenance therapy after the successful
eradication of
H. pylori (12). However, some doctors in charge of GU
patients still use acid blockers and mucosal protectants to protect gastric
mucosa since chronic gastritis can continue even after the
H. pylori
are eradicated. This maintenance therapy would increase the cost of therapy
unnecessarily. In the GUGLJ, the maintenance therapy is recommended to be performed
only for the GU patients who are not subjects of eradication therapy. Considering
the treatment under the limited budgets of health care insurance, the aspect
of cost-effectiveness is an essential issue for the overall treatment. However,
in the present study,
H. pylori infection was assessed for 66.5% of the
GU patients, and only 26.7% succeeded in
H. pylori eradication. Then,
only 24.4% had no maintenance therapy following the eradication while 60.8%
received H
2RA. These results may indicate the
low coverage of GUGLJ among the doctors in charge for GU patients in Japan during
the period of the present study performed. Indeed, there were 712 GI experts
but only 325 knew GUGLJ well in the present study.
When estimating the cost-effectiveness of medical treatment, it is important to be clear on what the effectiveness is intended for. Basically, the medical cost expended must include not only the direct performance on the patients but also the indirect performance such as loss of social activity relating to the hospitalization of the patients in the hospital. In the present study, however, the economic estimation could cover the direct performances for the GU patients who consulted the NHO hospitals on a regular basis and enrolled within the following nine months after the diagnosis of GU. As a result, the different categories of GU therapy could not influence on the GU recurrence, but may influence on the medical cost consumed.
The different medical costs of categories 1 to 4 were attributed mainly to the different cost of drugs prescribed, and the fees of inpatient hospitalization, the latter of which would reflect the duration of hospitalization. As mentioned before, the GU patients in category 4 complained less PCS of QOL than the other GU patients. This would mean those GU patients in category 4 had fewer complications or complaints relating to the shorter time of GU healing, or both. So, it may be possible to consider that they had the least consumption of drugs prescribed, and the smallest fees of the inpatient hospitalization.
GU therapy may be requested if it recurs even five years after the diagnosis of GU. Indirect influence of the GU patients on the economics would vary according to their social activities. In the present study, the adherence scores of the GU patients were not assessed. The medical costs were evaluated by accounting for the direct performance within limited periods. Therefore, the data obtained in the present study could reflect only the adherence of medical professionals, and then some parts of the total cost expended. However, the results obtained in the present study could reflect the practical medicine performed for the GU therapy in Japan, as evaluated from the view points of medical professionals. The present study could conclude that the therapy for GU along with the GUGLJ is essential to perform a cost-effective medicine and it is most effectively performed by the GI experts or the doctors who understand very well the GUGLJ.
Acknowledgements:
The present study named EGGU was supported financially by National Hospital
Organization of Japan.
Conflict of interests: None declared.
REFERENCES
- Research group for assesment and adaptation of guideline for gastric ulcer. Evidence-based guideline for gastric ulcer treatment (in Japanese). Tokyo, Jiho K.K., 2003.
- Research group for assesment and adaptation of guideline for gastric ulcer. Evidence-based guideline for gastric ulcer treatment (in Japanese). 2nd Ed. Tokyo, Jiho K.K., 2007.
- Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 1999; 281: 1900-1905.
- Uemura N, Okamoto S, Taniyama K, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789.
- Fukuhara S, Suzukamo Y. Manual of SF-36v2 Japanese version (in Japanese). Kyoto, Institute for Health Outcomes & Process Evaluation Research, 2004.
- Karczewska E, Wojtas I, Sito E, et al. Assessment of co-existence of Helicobacter pylori and Candida fungi in diseases of the upper gastrointestinal tract. J Physiol Pharmacol 2009; 60(Suppl 6): 33-39.
- Loster BW, Czesnikiewicz-Guzik M, Bielanski W, et al. Prevalence and characterization of Helicobacter pylori (H. pylori) infection and colonization in dentists. J Physiol Pharmacol 2009; 60(Suppl 8): 13-18.
- Sugiyama T. Gastric ulcer. In: Helicobacter pylori and the Eradication Therapy (in Japanese). Terano A, Takahashi S, (eds.) Tokyo, Nankodo, 2003, pp. 31-36.
- Nomura A, Stemmermann GN, Chyou PH, Perez-perez GI, Blaser MJ. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994; 120: 977-981.
- Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
- Sung JJ, Chung SC, Ling TK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995; 332: 139-142.
- Labenz J, Leverkus F, Borsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol 1994; 29: 1070-1075.